PriceTargets.com logo

Aadi Bioscience - AADI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $34.50
  • Forecasted Upside: 591.38%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$4.99 As of 12/1/2023 09:54 PM ET
▼ -0.27 (-5.13%)

This chart shows the closing price for AADI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aadi Bioscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AADI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AADI

Analyst Price Target is $34.50
▲ +591.38% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Aadi Bioscience in the last 3 months. The average price target is $34.50, with a high forecast of $36.00 and a low forecast of $33.00. The average price target represents a 591.38% upside from the last price of $4.99.

This chart shows the closing price for AADI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Aadi Bioscience. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/13/2023HC WainwrightLower TargetBuy ➝ Buy$45.00 ➝ $36.00Low
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$45.00N/A
5/11/2023LADENBURG THALM/SH SHLower Target$47.00 ➝ $33.00Low
3/29/2023HC WainwrightLower TargetBuy$48.00 ➝ $45.00Low
11/15/2022LADENBURG THALM/SH SHLower Target$47.00N/A
5/12/2022Piper SandlerLower Target$50.00 ➝ $30.00High
4/11/2022HC WainwrightLower TargetBuy$49.00 ➝ $48.00Medium
1/11/2022Jefferies Financial GroupInitiated CoverageBuy$45.00High
11/24/2021HC WainwrightBoost TargetBuy$47.00 ➝ $49.00Medium
10/1/2021CowenInitiated CoverageOutperformMedium
9/14/2021LADENBURG THALM/SH SHInitiated CoverageBuy$51.00Low
9/8/2021Piper SandlerInitiated CoverageOverweight$45.00High
8/30/2021HC WainwrightBoost TargetBuy$22.00 ➝ $47.00N/A
7/8/2021HC WainwrightUpgradeNeutral ➝ BuyHigh
3/15/2021HC WainwrightReiterated RatingHoldMedium
12/14/2020HC WainwrightReiterated RatingNeutral$15.00 ➝ $11.25High
12/9/2020BTIG ResearchInitiated CoverageBuy$30.00High
9/17/2020HC WainwrightReiterated RatingHold$15.00High
8/13/2020HC WainwrightBoost TargetNeutral$11.25 ➝ $15.00High
6/25/2020HC WainwrightBoost TargetNeutral$7.50 ➝ $11.25High
5/28/2020HC WainwrightReiterated RatingHold$7.50High
2/10/2020HC WainwrightReiterated RatingHold$7.50Low
10/21/2019HC WainwrightSet TargetHold$7.50Low
8/9/2019HC WainwrightReiterated RatingHold$7.50Medium
6/12/2019HC WainwrightReiterated RatingNeutralLow
6/12/2019HC WainwrightInitiated CoverageNeutral$7.50Low
5/10/2019HC WainwrightReiterated RatingHoldHigh
4/5/2019HC WainwrightReiterated RatingHoldLow
3/19/2019HC WainwrightDowngradeBuy ➝ NeutralHigh
3/18/2019GuggenheimDowngradeBuy ➝ NeutralHigh
3/18/2019National SecuritiesDowngradeBuy ➝ NeutralN/A
3/6/2019HC WainwrightReiterated RatingBuyLow
3/5/2019Cantor FitzgeraldSet TargetBuy$60.00Low
2/11/2019Cantor FitzgeraldSet TargetBuy$60.00Low
1/18/2019Cantor FitzgeraldReiterated RatingOverweightMedium
1/18/2019Cantor FitzgeraldInitiated CoverageOverweight$60.00High
(Data available from 12/4/2018 forward)

News Sentiment Rating

0.19 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/8/2023
  • 1 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2023
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/5/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/4/2023
  • 1 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2023

Current Sentiment

  • 1 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Aadi Bioscience logo
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus bound to albumin. The company is also involved in evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Read More

Today's Range

Now: $4.99
Low: $4.96
High: $5.37

50 Day Range

MA: $4.56
Low: $3.94
High: $5.41

52 Week Range

Now: $4.99
Low: $3.88
High: $13.60

Volume

95,800 shs

Average Volume

89,772 shs

Market Capitalization

$122.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07

Frequently Asked Questions

What sell-side analysts currently cover shares of Aadi Bioscience?

The following Wall Street analysts have issued research reports on Aadi Bioscience in the last year: HC Wainwright, and LADENBURG THALM/SH SH.
View the latest analyst ratings for AADI.

What is the current price target for Aadi Bioscience?

2 Wall Street analysts have set twelve-month price targets for Aadi Bioscience in the last year. Their average twelve-month price target is $34.50, suggesting a possible upside of 591.4%. HC Wainwright has the highest price target set, predicting AADI will reach $36.00 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $33.00 for Aadi Bioscience in the next year.
View the latest price targets for AADI.

What is the current consensus analyst rating for Aadi Bioscience?

Aadi Bioscience currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AADI will outperform the market and that investors should add to their positions of Aadi Bioscience.
View the latest ratings for AADI.

What other companies compete with Aadi Bioscience?

Other companies that are similar to Aadi Bioscience include Ventyx Biosciences, Omeros, Annexon, I-Mab and OptiNose. Learn More about companies similar to Aadi Bioscience.

How do I contact Aadi Bioscience's investor relations team?

Aadi Bioscience's physical mailing address is 9987 Carver Rd, Blue Ash, Ohio 45242-5550. The company's listed phone number is (424) 473-8055 and its investor relations email address is [email protected]. The official website for Aadi Bioscience is aadibio.com. Learn More about contacing Aadi Bioscience investor relations.